Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11385841 | 0.82 | L3MBTL1 (0.71) | L3MBTL1MAPTNPSR1RAB9ASMN1; SMN2 | |
| SCHEMBL3965371 | 0.80 | L3MBTL1 (0.78) | L3MBTL1MAPTNPSR1RAB9ALMNA | |
| SCHEMBL4697665 | 0.79 | L3MBTL1 (0.56) | L3MBTL1MAPTNPSR1RAB9ASMN1; SMN2 | |
| SCHEMBL890750 | 0.79 | L3MBTL1 (0.56) | L3MBTL1MAPTNPSR1RAB9ALMNA | |
| SCHEMBL31090839 | 0.78 | L3MBTL1 (0.81) | L3MBTL1MAPTNPSR1RAB9ASMN1; SMN2 | |
| SCHEMBL14681242 | 0.78 | L3MBTL1 (0.81) | L3MBTL1MAPTNPSR1RAB9ASMN1; SMN2 | |
| SCHEMBL2031421 | 0.78 | ALDH1A1 (0.53) | L3MBTL1SMN1; SMN2LMNAALDH1A1TDP1 | |
| SCHEMBL7390045 | 0.78 | CYP1A2 (0.66) | L3MBTL1MAPTNPSR1SMN1; SMN2LMNA | |
| SCHEMBL8935331 | 0.78 | L3MBTL1 (0.69) | L3MBTL1MAPTNPSR1RAB9ALMNA | |
| SCHEMBL2932928 | 0.78 | LMNA (0.51) | MAPTSMN1; SMN2LMNAALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540372-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-01-10 | — | — | US | disclosed |
| US-9540372-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-01-10 | — | — | US | disclosed |
| US-9540372-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-01-10 | — | — | US | disclosed |
| US-20160002230-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-20160002230-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-20160002230-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-9155737-B2 | Pyrido[2,3-B]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-10-13 | — | — | US | disclosed |
| US-9155737-B2 | Pyrido[2,3-B]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-10-13 | — | — | US | disclosed |
| US-9155737-B2 | Pyrido[2,3-B]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-10-13 | — | — | US | disclosed |
| US-20150182526-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-07-02 | — | — | US | disclosed |
| US-20120238568-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-09-20 | — | — | US | disclosed |
| US-8198279-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-06-12 | — | — | US | disclosed |
| US-8198279-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-06-12 | — | — | US | disclosed |
| US-8198279-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2229391-A1 | PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077766-A1 | PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077766-A1 | PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238568-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | L3MBTL1 3197/4885MAPT 3004/4885NPSR1 3311/4885 |
| US-20150182526-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | BRAF, NRAS, RAF1 | L3MBTL1 3197/4885MAPT 3004/4885NPSR1 3311/4885 |
| US-20160002230-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | BRAF, NRAS, RAF1 | L3MBTL1 3197/4885MAPT 3004/4885NPSR1 3311/4885 |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | L3MBTL1 3197/4885MAPT 3004/4885NPSR1 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.